Vertex Pharmaceuticals VRTX EV / EBITDA
EV / EBITDA at other companies
Other financials
Where this comes from
Calculated from Vertex Pharmaceuticals’s reported figures.
Based on the most recent quarter.
The official record: Vertex Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vertex Pharmaceuticals's ev / ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Vertex Pharmaceuticals's EV / EBITDA?
- Vertex Pharmaceuticals (VRTX) reported EV / EBITDA of 22.4× in Q1 2026.
- What is the long-term trend for Vertex Pharmaceuticals's EV / EBITDA?
- Over 2 years (2021 to 2023), Vertex Pharmaceuticals's EV / EBITDA has grown at a 8.5% compound annual growth rate (CAGR), from 72.2× to 85×.
- What does EV / EBITDA mean?
- What the whole business (debt included) costs relative to its operating cash earnings.
- How do you interpret EV / EBITDA?
- Lets you compare companies with different leverage and tax positions on a like-for-like basis — the standard multiple in M&A. Lower can mean cheaper, subject to growth and capital intensity.
- How does EV / EBITDA compare across companies?
- Broadly comparable across non-financial sectors; not used for banks and insurers, where EBITDA is not meaningful.